MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.31 -2.96

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.3

Máximo

1.37

Métricas clave
By Trading Economics
Ingresos	2.7M -24M
BPA	-0.354
Empleados	49
EBITDA	-5.3M -28M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+97.78% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-8.4M 73M
Apertura anterior	4.27
Cierre anterior	1.31

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 abr 2026, 23:17 UTC

Ganancias

Samsung Forecasts Record First-Quarter Operating Profit

6 abr 2026, 23:00 UTC

Acciones populares

Stocks to Watch: Health Insurers, Mawson, Owlet

6 abr 2026, 22:13 UTC

Principales Movimientos del Mercado

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 abr 2026, 21:46 UTC

Adquisiciones, fusiones, absorciones

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 abr 2026, 17:09 UTC

Principales Movimientos del Mercado

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 abr 2026, 16:56 UTC

Noticias de Eventos Importantes

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 abr 2026, 14:47 UTC

Principales Movimientos del Mercado

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 abr 2026, 00:00 UTC

Noticias de Eventos Importantes

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 abr 2026, 23:58 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 abr 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 abr 2026, 23:36 UTC

Charlas de Mercado

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 abr 2026, 23:15 UTC

Charlas de Mercado

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 abr 2026, 22:52 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

6 abr 2026, 22:52 UTC

Charlas de Mercado

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 abr 2026, 22:14 UTC

Charlas de Mercado

Correction to Live Cattle Futures Article

6 abr 2026, 20:56 UTC

Charlas de Mercado

Mexican Private Consumption Fell in January -- Market Talk

6 abr 2026, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

6 abr 2026, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 abr 2026, 19:58 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 abr 2026, 19:58 UTC

Charlas de Mercado

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 abr 2026, 19:11 UTC

Charlas de Mercado

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 abr 2026, 19:06 UTC

Charlas de Mercado

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 abr 2026, 19:03 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

6 abr 2026, 19:03 UTC

Charlas de Mercado

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 abr 2026, 18:36 UTC

Adquisiciones, fusiones, absorciones

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 abr 2026, 17:59 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 abr 2026, 17:13 UTC

Adquisiciones, fusiones, absorciones

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 abr 2026, 16:33 UTC

Charlas de Mercado

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 abr 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 abr 2026, 14:59 UTC

Ganancias

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

97.78% repunte

Estimación a 12 Meses

Media 2.67 USD 97.78%

Máximo 3 USD

Mínimo 2 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.